A phase II trial this week showed that combining the diabetes drug semaglutide (Novo Nordisk A/S) with a fixed-dose combination of Cagrisema (cagrilintide/semaglutide) led to “numerically higher” reductions in both HbA1c and body weight than either component alone. And on the preclinical side, researchers from the Novo Nordisk Research Center and the Helmholtz Diabetes Center reported that linking the dual PPAR activator tesaglitazar to GLP-1 improved glucose control in male mice. Both bits of news illustrate that GLP-1R agonists, which are also called incretin mimetics and GLP-1 analogs, are likely to continue their success across multiple areas of medical care.

Carmot Therapeutics Inc. has raised $160 million in series D financing to support a trio of early to midstage clinical programs focused on treating diabetes and obesity with peptide-based small-molecule incretin receptor modulators.

Eli Lilly and Co.'s tirzepatide, a high-profile entrant in the global anti-obesity race, hit a key milestone, becoming the first investigational medicine to deliver more than 20% weight loss on average for non-diabetics in a phase III study, said Jeff Emmick, vice president of product development at the company.

A Korean study led by Seoul National University scientists is the first to demonstrate that the human intestinal mucin-degrading bacterium, Akkermansia muciniphila, secretes a glucagon-like peptide-1 (GLP-1)-inducing protein, which significantly improved glucose homeostasis and ameliorated metabolic disease in mice.